MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co free cash flow 1989–2026

Merck & Co's free cash flow in Q3 FY2026, the three months to 30 September 2026, was 5.52B USD, down 19.3% on the same quarter a year before. Merck & Co's free cash flow over the last twelve months was 14.75B USD, up 13.0% on the twelve months before. In fiscal year 2025 it was 12.36B USD, down 31.7% on the year before.

Last updated 7 Nov 2026 · Next report 2 Feb 2027

Free cash flow

Free cash flow · +1.0% a year over 10 yearsFree cash flow margin

Growth

Fiscal yearPeriod endingFree cash flowGrowthFree cash flow marginOperating cash flowCapital expenditureFree cash flow per share
TTM30 Sept 202614.75B+13.00%21.91%18.70B-3.96B5.95
FY202531 Dec 202512.36B-31.70%19.04%16.47B-4.11B4.93
FY202431 Dec 202418.10B+97.92%28.20%21.47B-3.37B7.12
FY202331 Dec 20239.14B-37.83%15.21%13.01B-3.86B3.59
FY202231 Dec 202214.71B+52.23%24.81%19.10B-4.39B5.79
FY202131 Dec 20219.66B+65.88%19.84%14.11B-4.45B3.81
FY202031 Dec 20205.82B-41.57%14.03%10.25B-4.43B2.29
FY201931 Dec 20199.97B+19.98%25.48%13.44B-3.47B3.86
FY201831 Dec 20188.31B+82.21%19.64%10.92B-2.62B3.10
FY201731 Dec 20174.56B-47.97%11.36%6.45B-1.89B1.66
FY201631 Dec 20168.76B-21.33%22.01%10.38B-1.61B3.14
FY201531 Dec 201511.14B+100.94%28.20%12.42B-1.28B3.92
FY201431 Dec 20145.54B-45.15%13.12%7.86B-2.32B1.89
FY201331 Dec 201310.11B+25.26%22.95%11.65B-1.55B3.37
FY201231 Dec 20128.07B-24.32%17.07%10.02B-1.95B2.62
FY201131 Dec 201110.66B+16.58%22.19%12.38B-1.72B3.45
FY201031 Dec 20109.14B+373.44%19.88%10.82B-1.68B2.93
FY200931 Dec 20091.93B-63.37%7.04%3.39B-1.46B0.85
FY200831 Dec 20085.27B-11.94%22.11%6.57B-1.30B2.46
FY200731 Dec 20075.99B+3.51%24.75%7.00B-1.01B2.73
FY200631 Dec 20065.79B-6.78%25.56%6.77B-980.20M2.64
FY200531 Dec 20056.21B-12.26%28.19%7.61B-1.40B2.82
FY200431 Dec 20047.07B-10.99%30.79%8.80B-1.73B3.18
FY200331 Dec 20037.95B+11.00%35.34%9.86B-1.92B3.53
FY200231 Dec 20027.16B+12.65%33.38%9.53B-2.37B3.14
FY200131 Dec 20016.36B+28.14%29.98%9.08B-2.72B2.74
FY200031 Dec 20004.96B+38.91%12.29%7.69B-2.73B2.11
FY199931 Dec 19993.57B+6.42%10.91%6.13B-2.56B1.48
FY199831 Dec 19983.35B-31.08%12.47%5.33B-1.97B1.37
FY199731 Dec 19974.87B+15.05%20.59%6.32B-1.45B1.97
FY199631 Dec 19964.23B+118.24%21.34%5.43B-1.20B1.70
FY199531 Dec 19951.94B-38.07%11.62%2.94B-1.01B0.76
FY199431 Dec 19943.13B+53.78%20.91%4.14B-1.01B1.23
FY199331 Dec 19932.04B+41.59%19.39%3.05B-1.01B0.87
FY199231 Dec 19921.44B+3.25%14.88%2.50B-1.07B0.76
FY199131 Dec 19911.39B+0.56%16.19%2.43B-1.04B0.60
FY199031 Dec 19901.38B+46.12%18.05%2.06B-670.80M0.59
FY198931 Dec 1989947.70M—14.47%1.38B-433.00M0.40

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow

Common questions about Merck & Co's free cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.